Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
Volume 6.99M
Average 14.09M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
Intrinsic Alpha fair value
Locked
Current Price
$7.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +40.9% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +40.9% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Genmab A/S NASDAQ:GMAB | $31.67B | $51.37 | Not rated | 18.7 | +66.73% |
BioNTech SE NASDAQ:BNTX | $21.22B | $85.60 | Not rated | -16.2 | -17.91% |
ImmunityBio, Inc. NASDAQ:IBRX | $6.40B | $6.02 | Not rated | -8.6 | +213.08% |
Legend Biotech Corporation NASDAQ:LEGN | $3.24B | $17.50 | Not rated | -21.4 | -41.96% |
Immunome, Inc. NASDAQ:IMNM | $2.22B | $18.77 | Not rated | -9.1 | -5.14% |
Replimune Group, Inc. NASDAQ:REPL | $2.08B | $21.89 | Not rated | -3.0 | +120.36% |
Immunocore Holdings plc NASDAQ:IMCR | $1.55B | $29.94 | Not rated | -77.5 | -28.82% |
Shattuck Labs, Inc. NASDAQ:STTK | $473.57M | $4.65 | Not rated | -10.9 | +128.06% |
Fate Therapeutics, Inc. NASDAQ:FATE | $149.20M | $1.28 | Not rated | -1.8 | +0.00% |
ALX Oncology Holdings Inc. NASDAQ:ALXO | $143.81M | $1.04 | Not rated | -0.9 | -34.01% |
Continue the stock analysis
Jump to another research area for this company.